Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000085832 | SCV001417294 | pathogenic | not provided | 2024-12-07 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 220 of the ABCA4 protein (p.Arg220Cys). This variant is present in population databases (rs61748538, gnomAD 0.007%). This missense change has been observed in individual(s) with Stargardt disease (PMID: 29854428, 29925512, 30093795). ClinVar contains an entry for this variant (Variation ID: 99471). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt ABCA4 protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. |
Ce |
RCV000085832 | SCV001961126 | likely pathogenic | not provided | 2021-07-01 | criteria provided, single submitter | clinical testing | |
Victorian Clinical Genetics Services, |
RCV002470767 | SCV002767272 | pathogenic | Severe early-childhood-onset retinal dystrophy | 2021-05-06 | criteria provided, single submitter | clinical testing | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with ABCA4-related disorders, including Stargardt disease 1 (MIM#248200). (I) 0106 - This gene is associated with autosomal recessive disease. However, pseudo-dominant inheritance has been suggested (PMID: 26527198). (I) 0115 - Variants in this gene are known to have variable expressivity (PMID: 31522899). (I) 0200 - Variant is predicted to result in a missense amino acid change from arginine to cysteine. (I) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD <0.01 for a recessive condition (v2: 2 heterozygotes, 0 homozygotes). (SP) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (v2) (6 heterozygotes, 0 homozygotes). (I) 0502 - Missense variant with conflicting in silico predictions and uninformative conservation. (I) 0604 - Variant is not located in an established domain, motif, hotspot or informative constraint region. (I) 0705 - No comparable missense variants have previous evidence for pathogenicity. (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. It has been reported in homozygote and compound heterozygote individuals with Stargardt disease (PMIDs: 19074458, 23953153, 25066811, 28041643, 29854428, 30093795), and in individuals with unstated zygosity (ClinVar; PMIDs: 24154662, 11328725). (SP) 0905 - No published segregation evidence has been identified for this variant. (I) 1007 - No published functional evidence has been identified for this variant. (I) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign |
Fulgent Genetics, |
RCV002498460 | SCV002805621 | likely pathogenic | Cone-rod dystrophy 3; Age related macular degeneration 2; Severe early-childhood-onset retinal dystrophy; Retinitis pigmentosa 19 | 2021-08-15 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV000504919 | SCV005070603 | likely pathogenic | Retinal dystrophy | 2017-01-01 | criteria provided, single submitter | clinical testing | |
Retina International | RCV000085832 | SCV000117975 | not provided | not provided | no assertion provided | not provided | ||
NIHR Bioresource Rare Diseases, |
RCV000504919 | SCV000599019 | likely pathogenic | Retinal dystrophy | 2015-01-01 | no assertion criteria provided | research |